Cytovance Biologics partnered with Vectron Biosolutions to add customized E. coli strain development to its microbial program. Leveraging Vectron’s vector engineering expression and secretion technology platforms, Cytovance will be able to offer customers more efficient options for E. coli-expressed products, with reduced downstream costs and processing time, and the full documentation of development work needed for regulatory approval. This aims to simplify and accelerate drug development ef...